Jonathan Schneck is listed as a director on 5 SEC Form D filings by 1 issuer between Feb 2012 and Feb 2015: NexImmune, Inc. (Gaithersburg, MD — biotechnology — 2012–2015; $21.7M reported sold to 69 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Kenneth Carter (5 shared filings), Alain Cappeluti (4 shared filings), James Barrett (2 shared filings), Janis Naeve (2 shared filings) and Slain Cappeluti (1 shared filing).
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Jonathan. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 5 public filings for Jonathan Schneck and found 3 differences, 2 worth asking the sponsor about: Form D filed 80 days after the first sale; Form D filed 241 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.